Login to Your Account



ASH 2011

Plenty in Myeloma Pipeline; What Regulatory Path Ahead?

By Anette Breindl
Science Editor

Monday, December 19, 2011

Multiple myeloma patients have gone from no options to three approved drugs in the past decade. And that fact is presumably part of what prompted the FDA's decision to refuse to give a priority review to Onyx Pharmaceuticals Inc.'s carfilzomib.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription